Abstract
METHODS
Hospital databases were searched over a 5-year period for patients undergoing both PET/CT and prostate magnetic resonance imaging (MRI). For the initial analysis, the prostate was divided into six sectors and suspicious or malignant sectors were identified using MRI and histopathology reports respectively. Maximum and mean 18 F-FDG standardised uptake values were measured in each sector by an investigator blinded to the MRI and histopathology findings. Two agematched controls were selected per case. Results were analysed using a paired t-test and one-way ANOVA. For the second analysis, PET/CT reports were searched for prostatic uptake reported incidentally and these patients were followed up.
INTRODUCTION
Positron emission tomography of 18 F-labelled fluorodeoxyglucose uptake combined with computed tomography ( 18 F-FDG PET/CT) is a mainstay of oncologic imaging. PET/CT imaging is well-tolerated and therefore has become a powerful tool for the diagnosis, staging and monitoring of many metabolically-active cancers. However, 18 F-FDG PET/CT imaging is not routinely used for detecting prostate cancer for both biological and technical reasons. Firstly, glucose uptake in well-differentiated prostatic adenocarcinoma is less avid than in many other cancers due to low glycolytic activity [1] . Secondly, urinary excretion of 18 F-FDG in the bladder and urethra can mask pathological uptake in the adjacent prostate. Thirdly, there is a large overlap in 18 F-FDG uptake between malignant disease, benign hyperplasia and inflammation of the prostate [1] . In men undergoing 18 F-FDG PET/CT for unrelated reasons, incidental prostatic uptake is found in 0.6%-2.8% of studies [1] [2] [3] [4] [5] . Although this is a small percentage of cases, it affects a large number of men given the growing number of PET/CT studies performed per year: 50000 annually in the UK and 2 million annually in the United States [6, 7] . The significance of such incidental uptake, together with the need for further investigation, is both uncertain and controversial.
A previous meta-analysis of prostatic uptake on 18 F-FDG PET/CT imaging showed that PET/CT cannot reliably differentiate benign from malignant disease, although only a small percentage of these patients underwent a definitive biopsy [8] . The published positive predictive value of 18 F-FDG uptake for detecting prostate cancer ranges between 30% (in a low-risk population of men with bladder cancer undergoing radical prostatectomy) to 65% [in a highrisk population of men undergoing prostate magnetic resonance imaging (MRI)] [9, 10] . Some studies argue that the positive predictive value is increased if 18 F-FDG uptake shows a high SUVmax, the lesion is in a peripheral location and the CT demonstrates a lack of calcification [11] [12] [13] . However, these features all show considerable overlap between malignant and benign disease.
Serum prostate-specific antigen (PSA), multiparametric prostate magnetic resonance imaging (mpMRI) and prostate biopsy can be used to investigate incidental prostatic 18 F-FDG uptake to determine if the patient has significant prostate cancer [5, 9] . However, there is no consensus on the management of patients with incidental prostatic 18 F-FDG uptake [9] . In order to better understand the significance of incidental prostatic 18 F-FDG uptake, we investigated both the correlation of prostatic 18 F-FDG uptake with findings from MRI and histopathology, and the impact on patient management of reporting increased 18 F-FDG uptake in the prostate.
MATERIALS AND METHODS

Study design and patient population
This single-institution retrospective study was approved locally, with the need for informed consent for data analysis waived. The hospital radiology database was searched to identify a total of 2846 18 F-FDG PET/CT studies performed on male patients in the period January 2010 to September 2015. For the first part of the study, 23 eligible men were identified who had both a prostate MRI and an 18 F-FDG PET/CT study. 15 of these men had prostate adenocarcinoma on ultrasound-guided biopsy or MRI/ultrasound fusion biopsy. Five men were excluded (the prostate cancer was treated prior to undergoing PET/CT in 4 patients, and one patient had > 4 years between MRI and PET/CT). For the second part of the study, the 18 F-FDG PET/CT reports were searched to identify patients with incidentally reported focal prostatic 18 F-FDG uptake. Patient records were examined for details of followup investigations and management. Two cases were included in both the first and second parts of the study. [14] . MRI reports were used to identify the prostatic sectors that were suspicious for tumour. Histopathology reports were used to identify the prostatic lobe(s) in which cancer had been detected. Sectorial analysis could not be performed for patients with no tumour focus on MRI, or bilateral tumour on histopathology ( Figure 1 ).
MRI and 18 F-FDG PET/CT analysis
Age-matched controls undergoing 18 F-FDG PET/CT but without prostate cancer were randomly selected for each case from PET/CT studies recently undertaken in the department; two controls for each case were acquired. Age matching within 18 mo was used as the criterion, and patients with a known tumour close to the prostate were excluded.
Statistical analysis
A paired two-tailed student's t-test was used to compare the 18 F-FDG uptake within suspicious or malignant sectors, with that in the remaining prostate for each individual patient. A paired two-tailed student's t-test was also used to compare prostatic 18 F-FDG uptake in patients with that from the controls. A one-way ANOVA was used to compare prostatic 18 F-FDG uptake between histopathological subgroups. Statistical analyses were performed using GraphPad Prism version 6.00 (GraphPad Software, La Jolla, CA, United States).
RESULTS
Eighteen patients who had both 18 F-FDG PET/CT and prostate MRI studies were included in the first part of the study. The median age was 72 years, median PSA was 7.30 ng/mL and median time difference between the 18 F-FDG PET/CT and the prostate MRI was 11.5 mo. See Table 1 for patient characteristics.
There was a trend for a higher 18 F-FDG uptake in prostatic sectors shown to be suspicious on MRI or F-FDG uptake was not significantly different between subgroups; we therefore found no correlation between prostatic 18 F-FDG uptake and the presence or grade of tumour confirmed on histopathology. Figure 3 illustrates a representative case of a 70-year-old man with highgrade prostate cancer that showed no uptake on PET/ CT. See Table 2 for mean values of SUVmax and SUVmean derived from sectorial, case-control and subgroup analysis.
For the second part of the study, 2846 male patients undergoing 18 F-FDG PET/CT over a 5-year period were followed-up. 46 men (1.6%) had an F-FDG uptake. 18 (0.6%) of these patients underwent further investigation. They had a median age of 68 years, median prostatic SUVmax of 7.80 and median PSA of 3.04 ng/mL. See Table 3 for patient characteristics.
Of these 18 men, 9 (0.3%) were referred to urology. Two men had a prostate biopsy, which showed benign disease and high-grade PIN respectively (Figure 4) . No cases of prostate cancer were diagnosed in the 5-year period. See Figure 5 for 
DISCUSSION
Prostate cancer is the commonest male cancer [15] . There is therefore a potentially high incidence of synchronous prostatic tumour in patients undergoing 18 F-FDG PET/CT for other indications. However, PET/CT lacks specificity and sensitivity for primary detection of prostate cancer; consequently it is unclear how patients with incidental tracer uptake in the prostate should be managed. Our study has shown that focal Prostate MRI alone (n = 1) which was normal Prostate biopsy (n =2) which showed benign tissue or high grade PIN PSA monitoring (n = 4) Lost to follow up (n = 2) Normal PSA (n = 4) Began palliative care (n = 3) Suspected prostatitis (n = 1) Uptake thought to be urethral on review (n = 1)
Chetan MR et al . Clinical significance of prostate 18 F-FDG uptake did not affect subsequent clinical management of any patient in our institute over a 5-year period.
Sector-based analysis showed that, in individual patients, malignant prostatic sectors had a trend to higher 18 F-FDG uptake than benign sectors. However, this difference was not statistically significant and total prostate 18 F-FDG uptake in men with prostate cancer was comparable to that from age-matched controls. Comparison of 18 F-FDG uptake across patient subgroups showed no correlation between 18 F-FDG uptake and histopathological findings. Although some authors have suggested that 18 F-FDG uptake weakly correlates with Gleason score, the small numbers in our study did not demonstrate this finding [9, 16] . In fact, we observed a higher SUVmax and SUVmean in patients with no biopsy, benign biopsy or high grade PIN than in patients with prostate cancer. This may be partially explained by increased 18 F-FDG uptake in prostatitis, where there is also increased glucose uptake within the inflammatory tissue [17] .
Incidental and unexplained prostate uptake was found in 1.6% of all 18 F-FDG PET/CT studies in male patients, which is comparable to the rate reported previously [3] [4] [5] . These patients had a median SUVmax of 7.8, which is suspicious for tumour; other authors have suggested an SUVmax greater than 6.0 should be considered as a cut-off value for high-grade prostate cancer [9] . Only 40% of patients with incidental and unexplained prostatic uptake were investigated with a serum PSA. Twenty percent of patients were referred to a urologist, and only one-third of these patients underwent further investigation with either biopsy or MRI. This may reflect the fact that the existing cancer diagnosis is the primary factor in determining clinical prognosis, and that the subsequent detection of prostate cancer would not significantly affect patient management due to unsuitability for radical therapy. Another possibility is a reluctance to perform a transrectal prostate biopsy in patients undergoing chemotherapy due to the risk of sepsis. In some patients, incidental prostatic uptake was not investigated for different reasons, e.g., uptake was thought to represent tracer in the urethra upon review (Figure 6 ), or uptake resolved on repeat PET/CT ( Figure  7 ). Ultimately over a 5-year period in our centre, involving nearly three thousand 18 F-FDG PET/CT studies, no change in patient management occurred as a result of an incidental finding of elevated prostatic 18 F-FDG uptake. Therefore, our retrospective study questions the need to investigate incidental prostatic uptake of 18 F-FDG in men undergoing PET/CT.
Our study has some limitations. Firstly, as a retrospective study our population consisted of patients who underwent 18 F-FDG PET/CT primarily for other malignancies, and therefore the time difference between PET/CT and MRI was long in some cases (up to 46 mo). This timescale is similar to previously reported retrospective studies and given that the natural history of prostate cancer is one of a slowgrowing tumour, most prostate cancers will be present for years before clinical presentation [10, 18] . Secondly, F-FDG uptake the number of eligible patients in our study was small. Thirdly, patients in our study had ultrasound-guided biopsy or MRI/ultrasound fusion biopsy, which are less sensitive in detecting prostate cancer than wholemount histology derived from prostatectomy samples.
In conclusion, 18 F-FDG uptake has low clinical utility in distinguishing benign and malignant prostatic disease. Reporting incidental prostatic uptake did not affect subsequent patient management or clinical outcomes in this cohort of patients. This study suggests there may be little benefit in investigating incidental elevated prostatic 18 F-FDG uptake on PET/CT which should be addressed with future large prospective studies.
COMMENTS
Background
18 F-labelled fluorodeoxyglucose ( 18 F-FDG) uptake on positron emission tomography/computed tomography (PET/CT) is used extensively in the diagnosis, staging and monitoring of many cancers. Incidental elevated prostatic 18 F-FDG uptake is found in a significant proportion of men undergoing PET/CT for unrelated reasons.
18 F-FDG PET/CT is not routinely used in prostate cancer because of the relatively low metabolic activity of prostate cancer, the proximity to tracer in the urethra and the presence of significant 
Research frontiers
The significance of incidental prostatic uptake, together with the need for further investigation, is unclear.
Innovations and breakthroughs
The results suggest that incidental prostatic uptake has no significant correlation with prostate magnetic resonance imaging or biopsy findings. In a cohort of nearly 3000 men over 5 years, reporting incidental prostatic 18 F-FDG uptake did not alter patient management or clinical outcomes.
Applications
The results suggest there is little benefit in investigating incidental elevated prostatic 18 F-FDG uptake.
